Please use this identifier to cite or link to this item: http://repositorio.unifesp.br/handle/11600/4933
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOmmati, Larissa Veloso Mendes [UNIFESP]
dc.contributor.authorRodrigues, Celso Arrais [UNIFESP]
dc.contributor.authorSilva, A.r. [UNIFESP]
dc.contributor.authorSilva, L.p. [UNIFESP]
dc.contributor.authorChauffaille, Maria de Lourdes Lopes Ferrari [UNIFESP]
dc.contributor.authorOliveira, José Salvador Rodrigues de [UNIFESP]
dc.date.accessioned2015-06-14T13:39:07Z
dc.date.available2015-06-14T13:39:07Z
dc.date.issued2009-03-01
dc.identifierhttp://dx.doi.org/10.1590/S0100-879X2009000300005
dc.identifier.citationBrazilian Journal of Medical and Biological Research. Associação Brasileira de Divulgação Científica, v. 42, n. 3, p. 244-250, 2009.
dc.identifier.issn0100-879X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/4933
dc.description.abstractAllogeneic hematopoietic stem cell transplantation (AHSCT) is the treatment of choice for young patients with severe aplastic anemia (SAA). The association of antithymocyte globulin (ATG) and cyclophosphamide (CY) is the most frequently used conditioning regimen for this disease. We performed this retrospective study in order to compare the outcomes of HLA-matched sibling donor AHSCT in 41 patients with SAA receiving cyclophosphamide plus ATG (ATG-CY, N = 17) or cyclophosphamide plus busulfan (BU-CY, N = 24). The substitution of BU for ATG was motivated by the high cost of ATG. There were no differences in the clinical features between the two groups, including age, gender, cytomegalovirus status, ABO match, interval between diagnosis and transplant, and number of total nucleated cells infused. No differences were observed in the time to neutrophil and platelet engraftment, or in the risk of veno-occlusive disease and hemorrhage. However, there was a higher risk of mucositis in the BU-CY group (71 vs 24%, P = 0.004). There were no differences in the incidence of neutrophil and platelet engraftment, acute and chronic graft-versus-host disease, and transplant-related mortality. There was a higher incidence of late rejection in the ATG-CY group (41 vs 4%, P = 0.009). Although the ATG-CY group had a longer follow-up (101 months) than the BU-CY group (67 months, P = 0.04), overall survival was similar between the groups (69 vs 58%, respectively, P = 0.32). We conclude that the association BU-CY is a feasible option to the conventional ATG-CY regimen in this population.en
dc.format.extent244-250
dc.language.isoeng
dc.publisherAssociação Brasileira de Divulgação Científica
dc.relation.ispartofBrazilian Journal of Medical and Biological Research
dc.rightsAcesso aberto
dc.subjectAplastic anemiaen
dc.subjectAllogeneic stem cell transplantationen
dc.subjectConditioning regimenen
dc.subjectATG-CYen
dc.subjectBU-CYen
dc.titleA retrospective comparison of cyclophosphamide plus antithymocyte globulin with cyclophosphamide plus busulfan as the conditioning regimen for severe aplastic anemiaen
dc.typeArtigo
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionHospital Santa Marcelina Serviço de Hematologia e Hemoterapia
dc.description.affiliationUniversidade Federal de São Paulo (UNIFESP) Escola Paulista de Medicina Departamento de Oncologia Clínica e Experimental
dc.description.affiliationHospital Santa Marcelina Serviço de Hematologia e Hemoterapia
dc.description.affiliationUnifespUNIFESP, EPM, Depto. de Oncologia Clínica e Experimental
dc.identifier.fileS0100-879X2009000300005.pdf
dc.identifier.scieloS0100-879X2009000300005
dc.identifier.doi10.1590/S0100-879X2009000300005
dc.description.sourceSciELO
dc.identifier.wosWOS:000264200100005
Appears in Collections:Artigo

Files in This Item:
File Description SizeFormat 
S0100-879X2009000300005.pdf67.99 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.